renal cell carcinoma

Episode Notes

Podcast Host Disclosures:

Dr. Choueiri reports institutional and/or personal, paid and/or unpaid support for research, advisory boards, consultancy, and/or honoraria from: Alkermes, AstraZeneca, Aravive, Aveo, Bayer, Bristol Myers-Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Gilead, IQVA, Infinity, Ipsen, Jansen, Kanaph, Lilly, Merck, Nikang, Nuscan, Novartis, Oncohost, Pfizer, Roche, Sanofi/Aventis, Scholar Rock, Surface Oncology, Takeda, Tempest, Up-To-Date, CME events (Peerview, OncLive, MJH, CCO and others), outside the submitted work. Institutional patents filed on molecular alterations and immunotherapy response/toxicity, and ctDNA. Equity: Tempest, Pionyr, Osel, Precede Bio, CureResponse, InnDura. Committees: NCCN, GU Steering Committee, ASCO/ESMO, ACCRU, KidneyCan. Medical writing and editorial assistance support may have been funded by Communications companies in part. No speaker’s bureau. Mentored several non-US citizens on research projects with potential funding (in part) from non-US sources/Foreign Components. The institution (Dana-Farber Cancer Institute) may have received additional independent funding of drug companies or/and royalties potentially involved in research around the subject matter. T. K. Choueiri is supported in part by the Dana-Farber/Harvard Cancer Center Kidney SPORE (2P50CA101942-16) and Program 5P30CA006516-56, the Kohlberg Chair at Harvard Medical School and the Trust Family, Michael Brigham, Pan Mass Challenge, Hinda and Arthur Marcus Fund and Loker Pinard Funds for Kidney Cancer Research at DFCI. 

Dr. Lalani has received honoraria from AbbVie, Astellas, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Ipsen, Janssen, McKesson, Merck, Novartis, Pfizer, Roche, TerSera. Funding for clinical trials directed to institutions from BMS (Inst), BioCanRx (Inst), Novartis (Inst), Roche (Inst), Ipsen (Inst), EMD Serrono (Inst).

Accreditation:

This podcast was accredited by the Canadian Urological Association in accordance with the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada. 

After completing the self-assessment questions at the link below, listeners are eligible to claim Section 3 self-assessment credits. 

Obtain Section 3 Credits Here >

[00:01:07] Thirty five years. Three decades and a half. Exactly. So I never said doc out. And it's actually part of my story that I was coined the hair doc about a decade ago. So I kind of go by the hair that. 

[00:02:14] So I will say I actually was volunteering as well. Iron ore, that's a big cancer facility in Arizona and I've been with them for 10 years. I also was a patient coordinator for the Look Good, Feel Good foundation. So when I was diagnosed with renal cell carcinoma, this isn't happening. I honestly was in denial for almost two years. I didn't do anything for about two years after that initial diagnosis, because when I went back to my support groups, I said, it's kind of weird. I have cancer. And they're like, what? Like you're the healthiest person on the planet? Because, you know, up until my second issue, which caused the cancer, which we'll talk about. I've been vegan pretty much my whole life. 

[00:03:51] So the three things were remove your kidney, which OK. Chemo, radiation. And take a drug test. I said, well, I don't really want to do any of that. Someone can figure it out for a second.

[00:04:57] So so what what is it for the audience out there? I mean, that they're diagnosed. I mean, what will be the one thing, one one piece of advice that you think would benefit them more than anything from your experience, your journey? What would that be? 

[00:05:50] They kind of think I'm crazy, but I started this charity called Superheroes. So I sometimes dress up in a Wonderwoman costume because I feel like that gets to them. And I explain to them that it's a mindset because I want to completely no chemo, no radiation. I wouldn't completely be in my face.

For more information about products and services discussed in this podcast, please visit www.integrativecancersolutions.com. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

In this episode, an expert medical oncology panel led by Elizabeth R. Plimack, MD, MS, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses clinical pearls for the management of patients with metastatic renal cell carcinoma (RCC). Topics include:

• Treating beyond progression with immunotherapy
• Management of patients with less common histologic subtypes of RCC
• Potential biomarkers for RCC
• Adverse event management

Presenters:

Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology 
Director, Genitourinary Clinical Research 
Professor, Department of Hematology/
Oncology 
Fox Chase Cancer Center 
Temple Health 
Philadelphia, Pennsylvania

Brian A. Costello, MD
Associate Professor of Oncology and Urology
Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Martin H. Voss, MD
Clinical Director, Genitourinary Medical Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor 
Weill Cornell Medical College
New York, New York

Content based on an online CME program supported by educational grants from Eisai, Exelixis, and Pfizer and EMD Serono.

Link to full program:
https://bit.ly/32IS9gx

In this episode, an expert medical oncology panel, led by Elizabeth R. Plimack, MD, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses current best practices for the second-line treatment and beyond of patients with metastatic renal cell carcinoma (RCC). Topics include:

•           Treatment sequencing with IO and TKI therapies

•           Optimizing dose for patients with preexisting toxicities

•           Considerations for local control of metastatic sites 

•           Ongoing clinical trials

Presenters:

Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology 
Director, Genitourinary Clinical Research 
Professor, Department of Hematology/Oncology 
Fox Chase Cancer Center 
Temple Health 
Philadelphia, Pennsylvania

Brian A. Costello, MD
Associate Professor of Oncology and Urology
Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Martin H. Voss, MD
Clinical Director, Genitourinary Medical Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor 
Weill Cornell Medical College
New York, New York

Content based on an online CME program supported by an educational grant from Eisai, Exelixis, and Pfizer and EMD Serono.

Link to full program:
https://bit.ly/32IS9gx

Discussion of childhood obesity, the topic of this week's main Editorial.

Continue this conversation on social!
Follow us today at...
https://twitter.com/thelancet
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv